PubMed

Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial.

Rosenstock J, Cefalu WT, Hollander PA, Klioze SS, Reis J, Duggan WT.

Diabetes Technol Ther. 2009 Nov;11(11):697-705.PMID: 19905885 [PubMed - in process]Related articles

Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine.

Rosenstock J, Eliaschewitz FG, Heilmann CR, Muchmore DB, Hayes RP, Belin RM.

Diabetes Technol Ther. 2009 Sep;11 Suppl 2:S63-73.PMID: 19772451 [PubMed - in process]Related articles

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.

Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q.

Diabetes Obes Metab. 2009 Dec;11(12):1145-52. Epub 2009 Sep 16.PMID: 19758359 [PubMed - in process]Related articles

Radiation therapy for preventing recurrence of neurogenic heterotopic ossification.

Cipriano C, Pill SG, Rosenstock J, Keenan MA.

Orthopedics. 2009 Sep;32(9). pii: orthosupersite.com/view.asp?rID=42854. doi: 10.3928/01477447-20090728-33.PMID: 19750999 [PubMed - in process]Related articles

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.

Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators.

Curr Med Res Opin. 2009 Oct;25(10):2401-11.PMID: 19650754 [PubMed - in process]Related articles

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M.

Diabetologia. 2009 Sep;52(9):1971-3. Epub 2009 Jul 16. No abstract available. PMID: 19609501 [PubMed - in process]Related articlesFree article

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.

Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group.

Diabetes Care. 2009 Oct;32(10):1880-6. Epub 2009 Jul 10.PMID: 19592625 [PubMed - in process]Related articles

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.

Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M.

Diabetologia. 2009 Sep;52(9):1778-88. Epub 2009 Jun 13.PMID: 19526210 [PubMed - in process]Related articlesFree article

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group.

Lancet. 2009 Jul 4;374(9683):39-47. Epub 2009 Jun 8.PMID: 19515413 [PubMed - indexed for MEDLINE]Related articles

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.

Rosenstock J, Niggli M, Maldonado-Lutomirsky M.

Diabetes Obes Metab. 2009 Jun;11(6):571-8. Epub 2009 Apr 5.PMID: 19383032 [PubMed - in process]Related articles

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial.

Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L.

BMC Neurol. 2008 Sep 16;8:33.PMID: 18796160 [PubMed - indexed for MEDLINE]Related articlesFree article

Fractionated stereotactic radiotherapy for the treatment of large arteriovenous malformations with or without previous partial embolization.

Veznedaroglu E, Andrews DW, Benitez RP, Downes MB, Werner-Wasik M, Rosenstock J, Curran WJ Jr, Rosenwasser RH.

Neurosurgery. 2008 Feb;62 Suppl 2:763-75.PMID: 18596429 [PubMed]Related articles

SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.

Rosenstock J, Hollander P, Chevalier S, Iranmanesh A; SERENADE Study Group.

Diabetes Care. 2008 Nov;31(11):2169-76. Epub 2008 Aug 4.PMID: 18678611 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents.

Rosenstock J, Bergenstal R, Defronzo RA, Hirsch IB, Klonoff D, Boss AH, Kramer D, Petrucci R, Yu W, Levy B; 0008 Study Group.

Diabetes Care. 2008 Nov;31(11):2177-82. Epub 2008 Aug 4.PMID: 18678610 [PubMed - indexed for MEDLINE]Related articlesFree article

Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes.

Rosenstock J, Cefalu WT, Hollander PA, Belanger A, Eliaschewitz FG, Gross JL, Klioze SS, St Aubin LB, Foyt H, Ogawa M, Duggan WT.

Diabetes Care. 2008 Sep;31(9):1723-8. Epub 2008 Jun 5.PMID: 18535196 [PubMed - indexed for MEDLINE]Related articlesFree article

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.

Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR.

Diabetes Care. 2008 Aug;31(8):1479-84. Epub 2008 May 5.PMID: 18458145 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy.

Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF.

Int Urol Nephrol. 2008;40(3):749-55. Epub 2008 Apr 26.PMID: 18438718 [PubMed - indexed for MEDLINE]Related articles

Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.

Rosenstock J, Fitchet M.

Int J Clin Pract Suppl. 2008 Mar;(159):15-23. Review.PMID: 18269437 [PubMed - indexed for MEDLINE]Related articles

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.

Rosenstock J, Sankoh S, List JF.

Diabetes Obes Metab. 2008 May;10(5):376-86. Epub 2008 Mar 18.PMID: 18355324 [PubMed - indexed for MEDLINE]Related articles

Management of prediabetes: setting the stage.

Rosenstock J.

Diabetes Obes Metab. 2007 Sep;9 Suppl 1:1-2. No abstract available. PMID: 17877540 [PubMed - indexed for MEDLINE]Related articles

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.

Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G.

Diabetologia. 2008 Mar;51(3):408-16. Epub 2008 Jan 16.PMID: 18204830 [PubMed - indexed for MEDLINE]Related articlesFree article

Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.

Rosenstock J, Chou HS, Matthaei S, Seidel DK, Hamann A.

Diabetes Obes Metab. 2008 Sep;10(10):862-73. Epub 2008 Jan 14.PMID: 18201206 [PubMed - indexed for MEDLINE]Related articles

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.

Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S.

Diabetes Obes Metab. 2008 Sep;10(10):931-8. Epub 2007 Dec 17.PMID: 18093207 [PubMed - indexed for MEDLINE]Related articles

Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!

Rosenstock J, Fonseca V.

Diabetes Care. 2007 Nov;30(11):2972-3. No abstract available. PMID: 17965313 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.

Diabetes Care. 2008 Jan;31(1):30-5. Epub 2007 Oct 18.PMID: 17947341 [PubMed - indexed for MEDLINE]Related articlesFree article

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.

Rosenstock J, Zinman B.

Curr Opin Endocrinol Diabetes Obes. 2007 Apr;14(2):98-107. Review.PMID: 17940427 [PubMed - indexed for MEDLINE]Related articles

Reflecting on type 2 diabetes prevention: more questions than answers!

Rosenstock J.

Diabetes Obes Metab. 2007 Sep;9 Suppl 1:3-11. Review.PMID: 17877541 [PubMed - indexed for MEDLINE]Related articles

Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy.

Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S.

Diabetes Care. 2008 Jan;31(1):20-5. Epub 2007 Oct 12.PMID: 17934150 [PubMed - indexed for MEDLINE]Related articlesFree article

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy.

Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, Dejager S.

Diabetes Care. 2007 Dec;30(12):3017-22. Epub 2007 Sep 18.PMID: 17878242 [PubMed - indexed for MEDLINE]Related articlesFree article

AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes.

Rosenstock J, Muchmore D, Swanson D, Schmitke J.

Expert Rev Med Devices. 2007 Sep;4(5):683-92. Review.PMID: 17850203 [PubMed - indexed for MEDLINE]Related articles

Distal support and community living among individuals diagnosed with schizophrenia and schizoaffective disorder.

Wieland ME, Rosenstock J, Kelsey SF, Ganguli M, Wisniewski SR.

Psychiatry. 2007 Spring;70(1):1-11.PMID: 17492907 [PubMed - indexed for MEDLINE]Related articles

A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.

Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A; OBD-202 Study Group.

Diabetes Care. 2007 Jun;30(6):1480-6. Epub 2007 Mar 15.PMID: 17363756 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures.

Rosenstock J, Nakano M, Silverman BL, Sun B, de la Peña A, Suri A, Muchmore DB.

Diabetes Technol Ther. 2007 Feb;9(1):80-8.PMID: 17316102 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S.

Diabetes Obes Metab. 2007 Mar;9(2):175-85.PMID: 17300593 [PubMed - indexed for MEDLINE]Related articles

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A.

Diabetes Care. 2007 Feb;30(2):217-23. Erratum in: Diabetes Care. 2007 May;30(5):1330. PMID: 17259484 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP.

Curr Med Res Opin. 2006 Dec;22(12):2575-90.PMID: 17166340 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.

Diabetes Obes Metab. 2006 Nov;8(6):650-60.PMID: 17026489 [PubMed - indexed for MEDLINE]Related articles

Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.

Rosenstock J, Rood J, Cobitz A, Huang C, Garber A.

Diabetes Obes Metab. 2006 Nov;8(6):643-9.PMID: 17026488 [PubMed - indexed for MEDLINE]Related articles

What are incretins, and how will they influence the management of type 2 diabetes?

Blonde L, Rosenstock J, Triplitt C.

J Manag Care Pharm. 2006 Sep;12(7 Suppl A):S2-12; quiz S14-6.PMID: 16981805 [PubMed - indexed for MEDLINE]Related articlesFree article

A life-threatening complication of Atkins diet.

Chen TY, Smith W, Rosenstock JL, Lessnau KD.

Lancet. 2006 Mar 18;367(9514):958. No abstract available. PMID: 16546552 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.

Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Peña A, Muchmore DB.

Diabetologia. 2006 May;49(5):891-9. Epub 2006 Feb 28.PMID: 16506054 [PubMed - indexed for MEDLINE]Related articles

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group.

JAMA. 2006 Feb 15;295(7):761-75. Erratum in: JAMA. 2006 Mar 15;295(11):1252. PMID: 16478899 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.

Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJ.

Curr Med Res Opin. 2005 Dec;21(12):2029-35.PMID: 16368054 [PubMed - indexed for MEDLINE]Related articles

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.

Rosenstock J, Goldstein BJ, Vinik AI, O'neill MC, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI; RESULT Study Group.

Diabetes Obes Metab. 2006 Jan;8(1):49-57.PMID: 16367882 [PubMed - indexed for MEDLINE]Related articles

Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease.

Dempster DW, Rosenstock JL, Schwimmer JA, Panagopoulos G, DeVita MV, Michelis MF.

Clin Nephrol. 2005 Nov;64(5):371-7.PMID: 16312265 [PubMed - indexed for MEDLINE]Related articles

Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial.

Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan SP, Cefalu WT.

Ann Intern Med. 2005 Oct 18;143(8):549-58.PMID: 16230721 [PubMed - indexed for MEDLINE]Related articlesFree article

Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine.

Garg SK, Rosenstock J, Ways K.

Endocr Pract. 2005 Jan-Feb;11(1):11-7. Erratum in: Endocr Pract. 2005 Mar-Apr;11(2):145. PMID: 16033730 [PubMed - indexed for MEDLINE]Related articles

Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.

Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G.

Nephrol Dial Transplant. 2005 Oct;20(10):2139-45. Epub 2005 Jul 19.PMID: 16030050 [PubMed - indexed for MEDLINE]Related articlesFree article